Covalent modification of human homeodomain interacting protein kinase 2 by SUMO-1 at lysine 25 affects its stability
- PMID: 15766567
- DOI: 10.1016/j.bbrc.2005.02.113
Covalent modification of human homeodomain interacting protein kinase 2 by SUMO-1 at lysine 25 affects its stability
Abstract
The HIPK2 protein is a critical regulator of apoptosis and functionally interacts with p53 to increase gene expression. Here we show that human HIPK2 is modified by sumoylation at lysine 25, as revealed by in vivo and in vitro experiments. While SUMO-1 modification of HIPK2 has no influence on its ability to phosphorylate p53 at serine 46, to induce gene expression, and to mediate apoptosis, a non-sumoylatable HIPK2 mutant displays a strongly increased protein stability. The N-terminal SUMO-1 modification site is conserved between all vertebrate HIPK2 proteins and is found in all members of the HIPK family of protein kinases. Accordingly, also human HIPK3 is modified by sumoylation.
Similar articles
-
Role of the SUMO-interacting motif in HIPK2 targeting to the PML nuclear bodies and regulation of p53.Exp Cell Res. 2011 Apr 15;317(7):1060-70. doi: 10.1016/j.yexcr.2010.12.016. Epub 2010 Dec 28. Exp Cell Res. 2011. PMID: 21192925
-
Regulation of homeodomain-interacting protein kinase 2 (HIPK2) effector function through dynamic small ubiquitin-related modifier-1 (SUMO-1) modification.J Biol Chem. 2005 Aug 12;280(32):29224-32. doi: 10.1074/jbc.M503921200. Epub 2005 Jun 15. J Biol Chem. 2005. PMID: 15958389
-
Negative regulation of beta4 integrin transcription by homeodomain-interacting protein kinase 2 and p53 impairs tumor progression.Cancer Res. 2009 Jul 15;69(14):5978-86. doi: 10.1158/0008-5472.CAN-09-0244. Epub 2009 Jun 30. Cancer Res. 2009. PMID: 19567674
-
Regulation of p53 activity by HIPK2: molecular mechanisms and therapeutical implications in human cancer cells.Oncogene. 2010 Aug 5;29(31):4378-87. doi: 10.1038/onc.2010.183. Epub 2010 May 31. Oncogene. 2010. PMID: 20514025 Review.
-
HIPK2: a multitalented partner for transcription factors in DNA damage response and development.Biochem Cell Biol. 2007 Aug;85(4):411-8. doi: 10.1139/O07-071. Biochem Cell Biol. 2007. PMID: 17713576 Review.
Cited by
-
PML activates transcription by protecting HIPK2 and p300 from SCFFbx3-mediated degradation.Mol Cell Biol. 2008 Dec;28(23):7126-38. doi: 10.1128/MCB.00897-08. Epub 2008 Sep 22. Mol Cell Biol. 2008. PMID: 18809579 Free PMC article.
-
SUMO conjugation regulates immune signalling.Fly (Austin). 2020 Mar-Dec;14(1-4):62-79. doi: 10.1080/19336934.2020.1808402. Epub 2020 Aug 31. Fly (Austin). 2020. PMID: 32777975 Free PMC article. Review.
-
HIPK2 is a new drug target for anti-fibrosis therapy in kidney disease.Front Physiol. 2015 Apr 28;6:132. doi: 10.3389/fphys.2015.00132. eCollection 2015. Front Physiol. 2015. PMID: 25972814 Free PMC article. Review.
-
Homeodomain-interacting protein kinase 2-dependent repression of myogenic differentiation is relieved by its caspase-mediated cleavage.Nucleic Acids Res. 2013 Jun;41(11):5731-45. doi: 10.1093/nar/gkt262. Epub 2013 Apr 24. Nucleic Acids Res. 2013. PMID: 23620283 Free PMC article.
-
Functional impairment of the HIPK2 small ubiquitin-like modifier (SUMO)-interacting motif in acute myeloid leukemia.Am J Cancer Res. 2019 Jan 1;9(1):94-107. eCollection 2019. Am J Cancer Res. 2019. PMID: 30755814 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Molecular Biology Databases
Research Materials
Miscellaneous